ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2022 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) updated its FY 2022 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.34-$1.62 for the period, compared to the consensus earnings per share estimate of $1.15. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $292.77 million.

A number of analysts recently weighed in on ANIP shares. StockNews.com downgraded shares of ANI Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, April 27th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, May 17th. Raymond James decreased their price target on shares of ANI Pharmaceuticals from $65.00 to $47.00 and set an outperform rating for the company in a research note on Wednesday, March 16th. Cantor Fitzgerald reissued a neutral rating on shares of ANI Pharmaceuticals in a research note on Wednesday, March 16th. Finally, TheStreet cut shares of ANI Pharmaceuticals from a c- rating to a d+ rating in a research note on Wednesday, March 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of Hold and an average price target of $56.67.

NASDAQ ANIP opened at $31.00 on Tuesday. The company has a current ratio of 3.79, a quick ratio of 2.74 and a debt-to-equity ratio of 0.89. The company has a fifty day simple moving average of $29.18 and a 200 day simple moving average of $37.45. ANI Pharmaceuticals has a 12-month low of $22.73 and a 12-month high of $60.23. The company has a market cap of $535.43 million, a P/E ratio of -6.84 and a beta of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.21). ANI Pharmaceuticals had a positive return on equity of 6.66% and a negative net margin of 27.78%. During the same period in the prior year, the firm earned $0.92 EPS. Sell-side analysts predict that ANI Pharmaceuticals will post 0.74 EPS for the current year.

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 17th. The stock was bought at an average price of $27.65 per share, for a total transaction of $138,250.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nikhil Lalwani bought 7,224 shares of the firm’s stock in a transaction that occurred on Monday, March 21st. The shares were acquired at an average price of $27.69 per share, with a total value of $200,032.56. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 17,224 shares of company stock valued at $477,083. 27.20% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in ANI Pharmaceuticals in the first quarter worth $64,000. PNC Financial Services Group Inc. grew its stake in shares of ANI Pharmaceuticals by 15.4% in the first quarter. PNC Financial Services Group Inc. now owns 3,828 shares of the specialty pharmaceutical company’s stock worth $108,000 after acquiring an additional 512 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of ANI Pharmaceuticals by 57.0% in the first quarter. MetLife Investment Management LLC now owns 5,858 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 2,127 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the third quarter worth $232,000. Finally, Amalgamated Bank purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $233,000. 59.66% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Read More

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.